Intended for healthcare professionals

News

Half of trials supporting new cancer drug approval in Europe had high risk of bias

BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5619 (Published 19 September 2019) Cite this as: BMJ 2019;366:l5619

Linked Research

Design characteristics, risk of bias, and reporting of RCTs supporting approvals of cancer drugs by EMA